This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at understanding the mechanisms underlying mast cell expansion and function in human airway diseases, including asthma and nasal polyposis. The $715,968 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, will fund a 5-year project to investigate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $612,328 to National Jewish Health to conduct research investigating how the transcription factor MITF regulates mast cell lineage commitment and function. The research aims to enhance understanding of the regulation of mast cell genes that influence allergy susceptibility and severity. Specifically, the grant will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $917,375 to Brigham & Women's Hospital Inc. to conduct research on defining the heterogeneous effector function of human mast cell subsets. The research aims to comprehensively characterize the cytokine, chemokine, and growth factor production profiles of in vitro-derived mast cell subtypes (MCT and...
This $2,016,357 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to characterize the role of transmembrane protein 178 (TMEM178) in bronchial epithelial cells and its impact on asthma pathogenesis. The key objectives are to: 1) investigate how TMEM178-mediated inhibition of calcium signaling is disrupted in asthmatic bronchial epithelial cells, 2) assess the effects of...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $462,501 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, to conduct research on mast cell activation as a common mechanism of pulmonary toxicity from chemical threat agents. The two-year project aims to examine how activation of mast cells contributes to lung inflammation and injury caused by exposure to various...
This Cooperative Agreement, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support comprehensive research on mapping airway epithelial cell-immune cell interactions in lung diseases like asthma and COPD. The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will receive $798,062 over the 5-year project period from September 2024 to August 2029. The research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the role of TGF-beta signaling in regulating T follicular helper (Tfh) cells and mast cell function, and how disruption of this pathway impacts allergic disease pathogenesis. The $162,000 award to the Trustees of Indiana University, Indianapolis will utilize a mouse model of Loeys-Dietz...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $586,250 to the University of Massachusetts Medical School (UMass Medical) to elucidate the pathways that lead to the differentiation of TFH13 cells, a novel T cell subset that drives the production of high-affinity, pathogenic IgE antibodies in allergic diseases. The overarching goal is to determine the distinct...
This $260,445 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify biomarkers associated with nasal polyp recurrence in patients with aspirin-exacerbated respiratory disease (AERD). The research aims to: 1) Establish a biomarker-based predictive model of nasal polyp recurrence in AERD patients based on tissue samples, using both type 2 and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $185,866 to the University of Vermont & State Agricultural College to investigate the role of airway epithelial syndecan-1 (SDC1) in a preclinical model of steroid-resistant severe allergic asthma. The key objectives are to evaluate the impact of macrophage-derived heparanase activity on SDC1 cleavage in...